Asthma efficacy
June 29, 2010
A NEW study, published in the
‘Annals of Allergy, Asthma and
Immunology’, has found that
adding once-daily Singular
(montelukast sodium) to the
corticosteriod inhalant, fluticasone,
is more effective in protecting
children aged 6-14 years against
exercise-induced asthma,
compared to adding the longacting
beta-agonist, salmeterol.
The study also found that
children treated with singular and
fluticasone also recovered faster
after exercise periods and had a
better response to the ‘quick-relief’
asthma medication, salbutamol.
“Introducing Singulair in children
not adequately controlled on ICS
alone can reduce their reliance on
reliever medication and optimise
their ability to perform daily
activities without the development
of the tolerance or tachyphylaxis to
short-acting beta-agonists such as
salbutamol which is seen with
salmeterol within weeks of regular
use,” said Professor Peter van
Asperen, Head of Department of
Respiratory Medicine at The
Children’s Hospital at Westmead.
The above article was sent to subscribers in Pharmacy Daily's issue from 29 Jun 10To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Jun 10
